Objective To explore the benazepril and atorvastatin calcium in treatment of primary hypertension and hyperlipemia in effect and safety. Methods 80 cases patients with primary hypertension and hyperlipemia were randomly divided into the investigation group (40 cases) and the control group (40 cases) ;The former took the benazepril and atorvastatin calcium,the latter took the valsartan and atorvastatin calcium. After six months of treatment,blood pressures、blood lipid and serum creatinine (Scr) 、blood urea nitrogen (BUN) 、24h urine protein were observed and compared. Results Blood lipid levels decreased after treatment in both groups, there was no significant difference between two group(P ＞ 0. 05); However, blood pressure and renal function indicators in the investigation group were better than those in the control group, there were significant difference between two group (P ＜ 0.05 ). Conclusion Benazepril and atorvastatin calcium for treating patients with primary hypertension and hyperlipemia can maintain steadily at lower level of blood pressures,improve the blood lipid indicators, protect renal function, and hence is worthy of being recommended in clinical practice.%目的探讨贝那普利联合阿托伐他汀钙治疗原发性高血压伴高血脂的临床疗效和安全性.方法 将80例原发性高血压伴高血脂患者随机分为观察组和对照组(各40例),观察组给予贝那普利联合阿托伐他汀钙治疗,对照给予缬沙坦联合阿托伐他汀钙治疗,治疗6个月后,观察比较两组患者血压、血脂水平和肾功能等各项指标.结果 治疗6个月后两组患者血脂水平均有明显改善,与治疗前比较,差异有统计学意义(P<0.01),但组间比较差异无统计学意义(P>0.05);观察组患者血压和肾功能指标好于对照组,差异有统计学意义(P<0.05).结论 贝那普利联合阿托伐他汀钙治疗原发性高血压伴高血脂,可以使患者血压持续稳定在较低水平,能改善血脂各项指标和保护肾功能.
展开▼
